2014
Impact of CD4+ Lymphocytes and HIV Infection on Anti‐Müllerian Hormone Levels in a Large Cohort of HIV‐infected and HIV‐uninfected Women
Scherzer R, Bacchetti P, Messerlian G, Goderre J, Maki PM, Seifer DB, Anastos K, Karim R, Greenblatt RM. Impact of CD4+ Lymphocytes and HIV Infection on Anti‐Müllerian Hormone Levels in a Large Cohort of HIV‐infected and HIV‐uninfected Women. American Journal Of Reproductive Immunology 2014, 73: 273-284. PMID: 25339186, PMCID: PMC4323676, DOI: 10.1111/aji.12332.Peer-Reviewed Original ResearchConceptsAnti-Müllerian hormone levelsUninfected womenHigh AMHHIV infectionCD4 countLymphocyte countHormone levelsCurrent CD4 countImpact of CD4Total lymphocyte countCD4 T cellsHormonal contraceptive useOvarian granulosa cell functionsGranulosa cell functionPast weight lossHIV viraemiaNadir CD4Undetectable viraemiaUninfected participantsAMH levelsLow AMHOvarian functionDetectable viraemiaT cellsLarge cohort
2013
Angiopoietin-1 and angiopoietin-2 are altered in polycystic ovarian syndrome (PCOS) during controlled ovarian stimulation
Tal R, Seifer DB, Grazi RV, Malter HE. Angiopoietin-1 and angiopoietin-2 are altered in polycystic ovarian syndrome (PCOS) during controlled ovarian stimulation. Vascular Cell 2013, 5: 18. PMID: 24156373, PMCID: PMC3895756, DOI: 10.1186/2045-824x-5-18.Peer-Reviewed Original ResearchPolycystic ovarian syndromeAng-2 levelsAng-1 levelsPCOS womenNumber of oocytesAng-2Ovarian stimulationRetrieval dayAngiopoietin-2Follicular fluidAng-1Angiopoietin-1Serum Ang-1 levelsSerum Ang-2 levelsAng-1/AngSerum Ang-1Prospective cohort studyOvarian hyperstimulationOvarian syndromeCohort studyOvarian functionCapillary leakageFF levelsDay 3Time points
2007
Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance
Seifer DB, MacLaughlin DT. Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance. Fertility And Sterility 2007, 88: 539-546. PMID: 17559842, DOI: 10.1016/j.fertnstert.2007.02.014.Peer-Reviewed Original ResearchConceptsPolycystic ovarian diseaseMullerian Inhibiting SubstanceOvarian reserveOvulation inductionInhibiting SubstanceDiagnosis of PCODRisk of OHSSOvarian growth factorsWidespread clinical useOvarian hyperstimulationOvarian diseaseOvarian functionMEDLINE reviewClinical significanceIntracycle variabilityEarly markerClinical useConventional markersDiagnostic markerGrowth factorSpecific cutIntercycle variabilityDifferent assaysMarkersDiagnosis
2005
Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment
Fleming R, Harborne L, MacLaughlin DT, Ling D, Norman J, Sattar N, Seifer DB. Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertility And Sterility 2005, 83: 130-136. PMID: 15652898, DOI: 10.1016/j.fertnstert.2004.05.098.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeDoses of metforminObese womenOvary syndromeMenstrual frequencyMetformin treatmentHormone changesReproductive hormone changesMonths of treatmentCohort of folliclesUniversity Teaching HospitalOvarian responseOvarian functionTeaching hospitalMAIN OUTCOMEMIS concentrationsProspective treatmentSubstance levelsMetforminMonthsWomenAssessment periodTreatmentSyndromeDoses
1998
Dimeric inhibin: a direct marker of ovarian aging
Danforth D, Arbogast L, Mroueh J, Kim M, Kennard E, Seifer D, Friedman C. Dimeric inhibin: a direct marker of ovarian aging. Fertility And Sterility 1998, 70: 119-123. PMID: 9660432, DOI: 10.1016/s0015-0282(98)00127-7.Peer-Reviewed Original ResearchConceptsInhibin B levelsPerimenopausal transitionOvarian reserveRegular menstrual cyclesPituitary FSH secretionDaily urine samplesSubsequent follicular phaseCorpus luteum functionYears of ageDay of ovulationWomen 39FSH levelsInhibin secretionFSH secretionPerimenopausal womenSerum levelsLH surgeProspective studyOvarian functionFollicular phaseMenstrual cycleFifth decadeMAIN OUTCOMEBlood samplesLuteal secretion